BusinessAkari Therapeutics Announces FDA Allowance of IND for Clinical Development of Coversin in PNHBy Nasdaq OMXJan 3, 2017, 12:01 PM UTC
BusinessAxsome Therapeutics Receives FDA Clearance of IND for Phase 2/3 Trial of AXS-05 in Alzheimer’s Disease AgitationBy Nasdaq OMXJan 3, 2017, 12:01 PM UTC
BusinessAxsome Therapeutics Receives FDA Clearance of IND for Phase 2/3 Trial of AXS-05 in Alzheimer’s Disease AgitationBy Nasdaq OMXJan 3, 2017, 12:01 PM UTC
BusinessFate Therapeutics Announces FDA Clearance of Investigational New Drug Application for ProTmune for Prevention of Acute GvHD and CMV InfectionBy Nasdaq OMXJan 26, 2016, 9:36 PM UTC
